

# The reporting quality of the interventional animal experiments in Chinese journals based on the evaluated results of the Animals in Research: Reporting In Vivo Experiments (ARRIVE) guidelines

**Bing Zhao**

Lanzhou University School of Basic Medical Sciences

**Yanbiao Jiang**

Lanzhou University School of Basic Medical Sciences

**Ting Zhang**

Lanzhou University School of Basic Medical Sciences

**Zhizhong Shang**

Lanzhou University School of Basic Medical Sciences

**Weiyi Zhang**

Lanzhou University

**Kaiyan Hu**

Lanzhou University

**Fei Chen**

Lanzhou University

**Fan Mei**

Lanzhou University

**Qianqian Gao**

Lanzhou University

**Li Zhao**

Lanzhou University

**Bin Ma** (✉ [kittymb2017@163.com](mailto:kittymb2017@163.com))

Evidence Based Medicine Center, School of Basic Medical Science <https://orcid.org/0000-0001-7247-8714>

**Joey S.W. Kwong**

Chinese University of Hong Kong

---

**Review**

**Keywords:** Animal experiments, ARRIVE, Reporting quality

**Posted Date:** May 28th, 2020

**DOI:** <https://doi.org/10.21203/rs.2.23896/v2>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

**Version of Record:** A version of this preprint was published on November 26th, 2020. See the published version at <https://doi.org/10.1186/s12917-020-02664-1>.

# Abstract

**Objective** To retrospectively evaluate the reporting quality of animal experiments published in Chinese journals adhering to the Animals Research: Reporting of In Vivo Experiments (ARRIVE) guidelines.

**Methods** The databases CNKI, WanFang, VIP, and CBM were searched from inception until July 2018. Two appropriately-trained reviewers screened and extracted articles independently. The ARRIVE guidelines were used to assess the quality of the published reports of animal experiments. The compliance rate of every item was analyzed relative to the different dates of publication.

**Results** A total of 4342 studies were finally included, of which 73.03% had been cited  $\leq 5$  times. Only 29.04% (1261/4342) were published in journals listed in the Chinese Science Citation Database. The results indicate that the compliance rate of around half of the sub-items (51.3%, 20/39) was less than 50% and 65.0% (13/20) was less than 10%.

**Conclusions** The reporting quality of animal experiments in Chinese journals is generally at a low to moderate level. Due to the publication of the ARRIVE guidelines in 2010, the compliance rate of the majority of items in the ARRIVE guidelines has improved to some extent. However, less attention has been paid to the ethics and welfare of experimental animals, and a number of specific items in the Methods, Results, and Discussion sections continue to not be reported in sufficient detail. Therefore, it is necessary to popularize the ARRIVE guidelines, advocate researchers to adhere to them in the future, and in particular promote the use of the guidelines in specialized journals, in order that the design, implementation, and reporting of animal experiments is promoted, to ultimately improve their quality.

## Introduction

Animal experimentation in scientific research is required to acquire new knowledge about biology and medicine or answer specific scientific questions<sup>[1]</sup>, and so represent a basic tenet of biomedical research. Animal experiments are also an important aspect of preclinical research. As a bridge between basic research and clinical trials, the quality of animal experiments affects the achievements and conclusions of research studies in many fields<sup>[2,3]</sup>.

Over recent years, the number of animal experiments published in biomedical journals has increased dramatically. Increasing numbers of studies have shown that<sup>[4-7]</sup>, even in animal experiments published in top journals, the quality of reporting remains unsatisfactory. A study by The National Centre for the Replacement, Refinement and Reduction of Animals in Research, the NC3Rs<sup>[8]</sup>, demonstrated that many funded animal experiments had inadequate reporting of important information such as study design, implementation, and analysis. In 271 animal experiments included in the review, 41% did not state the hypothesis or objective of the study or the number and basic characteristics of the animals used in the experiments, and 30% of them did not describe the statistical methods and did not present the results with correct statistical indicators. In addition, good animal welfare is closely related to the reliability and

repeatability of animal experiments. Seeking new methods to better promote animal welfare is also a concern of the 3Rs center<sup>[9]</sup>. The inadequacy and incompleteness of the quality of articles and poor quality of reports have seriously hindered the utilization of the scientific and practical value of those animal experiments. Therefore, in order to improve the quality of animal experimental reports, based on the CONSORT Statement<sup>[10]</sup>, the NC3Rs developed the ARRIVE (Animal Research: Reporting of In Vivo Experiments) guidelines, which were published in 2010. The guidelines consist of six parts: title, abstract, introduction, methods, results, and discussion, with 20 items and sub-items<sup>[11]</sup>. Since 2010, researchers outside China have studied the quality of animal experimental reports published in foreign journals based on the ARRIVE guidelines<sup>[12, 13, 14]</sup>, whereas in China, similar research has only been published by Liu *et al.*<sup>[15]</sup>. Furthermore, their research is limited to specific diseases. In addition, no studies have explored whether publication of the ARRIVE guidelines has improved the quality of animal experimental reports.

Therefore, the aim of this study was to comprehensively collect animal experimental results published in China, and to review and analyze the quality of the experimental reports based on the ARRIVE guidelines, in order to provide a reference that would promote the quality of animal experimental reports in China.

## Methods And Materials

### Patient and Public Involvement

No patients or members of the public were involved in this study.

### Inclusion and Exclusion criteria

**Inclusion criteria** Intervention animal experiments with no restriction/limitation on animal species or type of intervention.

**Exclusion criteria** Republished studies; Non-medical animal experiments; In vitro experiments based on animal tissues, organs or cells; Experiments involving both animals and humans; Relevant journals in Hong Kong, Macao, or Taiwan, which are limited by the authority.

### Search strategy

Searches of the Chinese Journal Full Text Database (CNKI), Chinese Academic Journal Database (Wanfang), Chinese Science and Technology Journal Database (VIP), and Chinese Biomedical Literature Database (CBM) from the inception of each database up to July 2018, were conducted. Search terms included: rats, rabbits, dogs, pigs, sheep, apes, frogs, orangutans, monkeys, animal experiments. A detailed search strategy for each database is presented in the S1 File.

### Methodological quality Control

Relevant training was conducted for the researchers (B.Z., Y.B.J., T.Z., Z.Z.S., W.Y.Z., K.Y.H., F.C., F.M., Q.Q.G., and L.Z.) who participated in the project, including gaining an understanding and interpretation of the content of the checklist of the ARRIVE guidelines, evaluation principles and methods, and procedures and methods of literature screening and data extraction. After training, the researchers were tested on independent literature screening, data extraction, and quality evaluation prior to the start of the formal study, using 10% of the literature selected for the formal review. Consistency of the evaluation was evaluated. With a Kappa value > 0.8, consistency was strong, and the training considered qualified.

### **Screened literature and extracted data**

Four of the trained reviewers (B.Z., Y.B.J., T.Z., and Z.Z.S.) independently screened, extracted and cross-checked studies based strictly on the inclusion and exclusion criteria. A third party (B.M.) made the final decision in case of disagreement. A full-text data extraction table was created in advance, and completed during the extraction process, recording ☐ basic characteristics of included studies: number of authors, the author's names, dates, journal, animal species, sample size, intervention measures, *etc.*; ☐ Information about all items relating to the ARRIVE guidelines.

### **Quality assessment of the included studies**

Three reviewers (W.Y. Z., K.Y.H., and F.C.) assessed the quality of the included studies based on the 39 sub-items of 20 items included in the ARRIVE guidelines. The evaluation results for each sub-item in the studies were deemed "high risk" or "low risk", where "low risk" was defined as a study that reported all or in part at least one of the information items of the sub-categories, in detail. Conversely, a paper was "high risk" if it did not. For example, in Item 6 (Study design, Table 2), the item would only be classified as "low risk" if at least one of the sub-items (6a-d) was reported, otherwise it would be classified as "high risk" (none of the 4 sub-items reported). Finally, the compliance rate of "low risk" for the 39 sub-items was calculated, *i.e.* the total number of studies with "low risk" relative to the total number of included studies.

### **Subgroup analysis**

Based on the year of publication (2010) of the ARRIVE guidelines, the included papers were analyzed comparatively (animal experiments published before 2010 vs. animal experiments published in 2010 and later). The "low risk" compliance rate of 39 sub-items of animal experiments published before 2010 and those published in 2010 or later was calculated, respectively, *i.e.* the number of papers, of which each sub-item was assessed as "low risk", accounted for the percentage of the total number of animal experiments pre-ARRIVE and post-ARRIVE, respectively.

### **Statistical analysis**

Data were analyzed using SPSS software (v21.0, SPSS, Chicago, IL). Categorical data are presented as frequency (n) and percentage (%). A chi-square test was performed to compare percentages between groups. P-values ☐ 0.05 were considered statistically significant.

# Results

## Selection process and results

A total of 21713 potentially relevant studies were initially selected. After excluding duplicates and those that did not fulfill the inclusion criteria, 4342 studies were finally included, in which 4925 animal experiments were conducted (as some included multiple animal experiments). The selection process and results are shown in Figure 1.

### Basic information of the studies included in the review

The number of citations for each included study ranged from 0 to 12. More than 70% (73.03%, 3171/4342) had been cited fewer than 5 times, of which nearly 50% (47.62%, 1510/3171) had not been cited at all. Only 29.04% (1261/4342) had been published in journals included in the Chinese Science Citation Database. The greatest proportion of first authors were clinicians (45.07%, 1957/4342) (Table 1).

**Table 1 Basic information of included studies**

Category	Feature	Total N (%)
Citation	0	1510 (34.78)
	1—5	1661 (38.25)
	≥5	1171 (26.97)
Categories of journals	Professional journals	1991 (45.86)
	Comprehensive journals	1654 (38.09)
	Others	697 (16.05)
Identities of the first author	Clinical doctors	1957 (45.07)
	Postgraduate students	740 (17.04)
	Researchers	1645 (37.89)

Of the 4925 animal experiments included in the review, the most frequently-used species of animal was the rat (81.26%, 4002/4925), then rabbits (15.07%, 742/4925), and dogs (1.91%, 94/4925). Of the type of intervention, the top three were drugs (82.23%, 4050/4925), surgery (7.39%, 364/4925), and acupuncture (3.70%, 182/4925) (Figure 2). In coverage and classification of related diseases, the top three were circulatory diseases (10.92%, 538/4925), digestive diseases (10.64%, 524/4925), and tumors (9.66%, 476/4925).

**Reporting quality of inclusive studies** (Figure 3, Table 2)

## Table 2 Assessment of reporting quality of included studies

Contact and Subject	Item	Description	Total		pre-ARRIVE		post-ARRIVE		$\chi^2$ value	P value
			items assessed as "low risk"		items assessed as "low risk"		items assessed as "low risk"			
			N	%	N	%	N	%		
<b>TITLE</b>										
	1	Provide as accurate and concise a description of the content of the article as possible.	4241	97.67	2196	97.13	2045	98.27	6.25	0.012
<b>ABSTRACT</b>										
	2	Provide an accurate summary of the background, research objectives (including details of the species or strain of animal used), key methods, principal findings, and conclusions of the study	4117	94.82	2084	92.17	2033	97.69	67.25	<0.001
<b>INTRODUCTION</b>										
Background	3a	Include sufficient scientific background (including relevant references to previous work) to understand the motivation and context for the study, and explain the experimental approach and rationale.	4071	93.76	2057	90.98	2014	96.78	62.36	<0.001
	3b	Explain how and why the animal species and model being used can address the scientific objectives and, where appropriate, the study's relevance to human biology.	1609	37.06	737	32.60	872	41.90	40.24	<0.001
Objectives	4	Clearly describe the primary and any secondary objectives of the study, or specific hypotheses being tested.	4248	97.84	2198	97.21	2050	98.51	8.60	0.003
<b>METHODS</b>										
Ethical statement	5	Indicate the nature of the ethical review permissions, relevant licenses (e.g. Animal [Scientific Procedures] Act 1986), and national or institutional guidelines for the care and use of animals, that cover the research.	286	6.59	125	5.53	161	7.74	8.59	0.003
Study design	6a	For each experiment, give brief details of the study design, including: the number of experimental and control groups.	3741	86.16	1893	83.72	1848	88.80	23.44	<0.001
	6b	For each experiment, give brief details of the study design, including: any steps taken to minimise the effects of subjective bias when	3961	91.23	2034	89.96	1927	92.60	9.43	0.002

		allocating animals to treatment (e.g., randomisation procedure) and when assessing results (e.g., if done, describe who was blinded and when).								
	6c	For each experiment, give brief details of the study design, including: the experimental unit (e.g. a single animal, group, or cage of animals).	4312	99.31	2245	99.26	2067	99.33	0.02	0.890
	6d	For each experiment, give brief details of the study design, including: A time-line diagram or flow chart can be useful to illustrate how complex study designs were carried out.	63	1.45	15	0.66	48	2.31	20.46	<0.001
Experimental procedures	7a	For each experiment and each experimental group, including controls, provide precise details of all procedures carried out. For example: How (e.g., drug formulation and dose, site and route of administration, anaesthesia and analgesia used [including monitoring], surgical procedure, method of euthanasia). Provide details of any specialist equipment used, including supplier(s).	4172	96.08	2165	95.75	2007	96.44	1.37	0.242
	7b	For each experiment and each experimental group, including controls, provide precise details of all procedures carried out. For example: When (e.g., time of day).	269	6.20	214	9.46	55	2.64	86.78	<0.001
	7c	For each experiment and each experimental group, including controls, provide precise details of all procedures carried out. For example: Where (e.g., home cage, laboratory, water maze).	513	11.81	309	13.67	204	9.80	15.53	<0.001
	7d	For each experiment and each experimental group, including controls, provide precise details of all procedures carried out. For example: Why (e.g., rationale for choice of specific anaesthetic, route of administration, drug dose used).	1631	37.56	806	35.65	825	39.64	7.38	0.007
Experimental animals	8a	Provide details of the animals used, including species, strain, sex, developmental stage (e.g., mean or median	4162	95.85	2160	95.53	2002	96.20	1.23	0.268

		age plus age range), and weight (e.g., mean or median weight plus weight range).								
	8b	Provide further relevant information such as the source of animals, international strain nomenclature, genetic modification status (e.g. knock-out or transgenic), genotype, health/immune status, drug- or testnaive, previous procedures, etc.	3785	87.17	1909	84.43	1876	90.15	31.68	<0.001
Housing and husbandry	9a	Housing (e.g., type of facility, specific pathogen free (SPF); type of cage or housing; bedding material; number of cage companions; tank shape and material etc. for fish).	1022	23.54	409	18.09	613	29.46	77.81	<0.001
	9b	Husbandry conditions (e.g., breeding programme, light/dark cycle, temperature, quality of water etc. for fish, type of food, access to food and water, environmental enrichment).	928	21.37	338	14.98	590	28.35	115.83	<0.001
	9c	Welfare-related assessments and interventions that were carried out before, during, or after the experiment.	147	3.39	77	3.41	70	3.36	0.01	0.939
Sample size	10a	Specify the total number of animals used in each experiment and the number of animals in each experimental group.	3440	79.23	1728	76.43	1712	82.27	22.47	<0.001
	10b	Explain how the number of animals was decided. Provide details of any sample size calculation used.	1	0.02	0	0.00	1	0.05	1.09	0.297
	10c	Indicate the number of independent replications of each experiment, if relevant.	6	0.14	4	0.18	2	0.10	0.51	0.474
Allocating animals to experimental groups	11a	Give full details of how animals were allocated to experimental groups, including randomization or matching if done.	522	12.02	208	9.20	314	15.09	35.54	<0.001
	11b	Describe the order in which the animals in the different experimental groups were treated and assessed.	4070	93.74	2100	92.88	1970	94.67	5.89	0.015
Experimental outcomes	12	Clearly define the primary and secondary experimental outcomes assessed (e.g., cell death, molecular markers, behavioral changes).	4071	93.76	2098	92.79	1973	94.81	7.55	0.006
Statistical methods	13a	Provide details of the statistical methods used for each analysis.	3585	82.57	1677	74.17	1908	91.69	230.97	<0.001

	13b	Specify the unit of analysis for each dataset (e.g. single animal, group of animals, single neuron).	2840	65.41	1287	56.92	1553	74.63	150.14	<0.001
	13c	Describe any methods used to assess whether the data met the assumptions of the statistical approach.	662	15.25	284	12.56	378	18.16	26.33	<0.001
<b>RESULTS</b>										
Baseline data	14	For each experimental group, report relevant characteristics and health status of animals (e.g., weight, microbiological status, and drug- or test-naïve) before treatment or testing (this information can often be tabulated).	223	5.14	87	3.85	136	6.54	16.06	<0.001
Numbers analysed	15a	Report the number of animals in each group included in each analysis. Report absolute numbers (e.g.10/20, not 50%)	3023	69.62	1546	68.38	1477	70.98	3.46	0.063
	15b	If any animals or data were not included in the analysis, explain why.	3213	74.00	1661	73.46	1552	74.58	0.70	0.402
Outcomes and estimation	16	Report the results for each analysis carried out, with a measure of precision (e.g, standard error or confidence interval).	3811	87.77	1918	84.83	1893	90.97	38.01	<0.001
Adverse events	17a	Give details of all important adverse events in each experimental group.	64	1.47	21	0.93	43	2.07	9.66	0.002
	17b	Describe any modifications to the experimental protocols made to reduce adverse events.	1	0.02	1	0.04	0	0.00	0.92	0.337
<b>DISCUSSION</b>										
Interpretation /scientific implications	18a	Interpret the results, taking into account the study objectives and hypotheses, current theory, and other relevant studies in the literature.	4157	95.74	2143	94.78	2014	96.78	10.62	0.001
	18b	Comment on the study limitations including any potential sources of bias, any limitations of the animal model, and the imprecision associated with the results.	228	5.25	103	4.56	125	6.01	4.59	0.032
	18c	Describe any implications of your experimental methods or findings for the replacement, refinement, or reduction (the 3Rs) of the use of animals in research.	15	0.35	4	0.18	11	0.53	3.89	0.048
Generalisability/translation	19	Comment on whether, and how, the findings of this study are likely to translate to other	281	6.47	134	5.93	147	7.06	2.32	0.128

		species or systems, including any relevance to human biology.								
Funding	20	List all funding sources (including grant number) and the role of the funder(s) in the study.	47	1.08	15	0.66	32	1.54	7.74	0.005

The ARRIVE guidelines have 6 sections with 20 items and 39 sub-items. The "low risk" compliance rate of around half of the sub-items (51.28%, 20/39) was less than 50%, of which a "low risk" compliance rate of 90% (18/20) was less than 30%, even 65% (13/20) was less than 10 % and only 28.21% (11/39) was higher than 90%.

□ Items relating to the title, abstract, and introduction

For items 1-2, involving the title and abstract, the "low risk" compliance rate was higher than 90%. The "low risk" compliance rate of items 1 and 2 in studies published after 2010 was higher than that of studies published before 2010. The differences between the two groups for both items 1 (P= 0.012) and 2 (P < 0.001) were statistically significant.

For items 3a-4, which involved the abstract, the "low risk" compliance rate was higher than 90%, although the "low risk" compliance rate of item 3b was only 37.06%. The "low risk" compliance rate of items 3a, 3b and 4 in studies published after 2010 was higher than that of studies published before 2010, and the differences between the two years of publication were statistically significant, for item 3a (P< 0.001), 3b (P< 0.001) and 4 (P= 0.003).

□ Items relating to methodology

For 28 items (items 5-13c) involving methodology, a "low risk" rate of compliance for items 6a, 6b, 6c, 7a, 8a, 8b, 10a, 11b, 12, 13a and 13b was greater than 50%. A "low risk" compliance rate of items 6b, 6c, 7a, 8a, 11b and 12 was greater than 90%, but less than 50% for items 5, 6d, 7b, 7c, 7d, 9a, 9b, 9c, 10b, 10c, 11a and 13c. Except for item 7d, the "low risk" rate of compliance in the latter group was less than 30%, and for items 5, 6d, 7b, 9c, 10b and sub-item 10c it was even less than 10%. The compliance rate for items 5, 6a, 6b, 6c, 6d, 7a, 7d, 8a, 8b, 9a, 9b, 10a, 10b, 11a, 11b, 12, 13a, 13b and 13c in studies published after 2010 was slightly higher than those before 2010. The differences between the two publication year groups were significantly different for items 5 (P= 0.003), 6a (P< 0.001), 6b (P= 0.002), 6d (P< 0.001), and 6d (P< 0.001), (P< 0.001), 7d (P= 0.007), 8a (P< 0.001), 9a (P< 0.001), 9b (P< 0.001), 10a (P< 0.001), 11a (P< 0.001), 11b (P< 0.015), 12 (P< 0.006), 13a (P< 0.001), 13b (P< 0.001) and 13c (P< 0.001), but not for 6c (P=0.890), 7a (P=0.242), 8a (P=0.268) or 10b (P=0.297). However, the "low risk" compliance rate for items 7b, 7c, 9c and 10c in studies published after 2010 was even lower

than in reports published before 2010. The difference between the two publication year groups for items 7b ( $P < 0.001$ ) and 7c ( $P < 0.001$ ) was significant, but not for items 9c ( $P = 0.939$ ) or 10c ( $P = 0.474$ ).

#### ▯ Items relating to the results and discussion

For items 14-17b involving the results, the "low risk" compliance rate of items 15a, 15b, and 16 was greater than 50%, while for items 14, 17a, and 17b it was less than 6%. The "low risk" compliance rate for items 14, 15a, 15b, 16 and 17a for studies published after 2010 were higher than in studies published after 2010. The differences between the two publication year groups for items 14 ( $P < 0.001$ ), 16 ( $P < 0.001$ ) and 17a ( $P = 0.002$ ) were significant, but not for items 15a ( $P = 0.063$ ), 15b ( $P = 0.402$ ) or 17b ( $P = 0.337$ ).

For items 18a-20 involving the discussion, except for the "low risk" compliance rate of item 18a, which was greater than 90%, that of the other items was lower than 10%. The "low risk" compliance rate of the 5 items in studies published after 2010 was higher than those of studies published prior to 2010. For items 18a ( $P = 0.001$ ), 18b ( $P = 0.032$ ), 18c ( $P = 0.048$ ), and 20 ( $P = 0.005$ ), the differences between the two publication year groups were significant but not for item 19 ( $P = 0.128$ ).

## Discussion

This is the first comprehensive and systematic study of the reporting quality of animal experiments published in Chinese journals based on the ARRIVE guidelines. Following publication of the guidelines, the compliance rate of the majority of items improved to a certain extent although there remains continued inadequacy in reports of specific items, *e.g.* study design, procedures, sample size, adverse events, and discussion.

### Methods section

High-quality research is inseparable from scientific design and rigorous implementation. These guidelines (ARRIVE) aim to maximize the output of animal research by optimizing the information provided in publications regarding experimental design, implementation, and analysis<sup>[11]</sup>. In the ARRIVE guidelines, methods include nine aspects: ethical statement, study design, experimental procedure, animals, housing and husbandry, sample size, allocation of animals to experimental groups, experimental outcomes, and statistical methods. The present research showed that:

▯ Ethical Statement: Of the animal studies published in Chinese journals, only 6.59% reported an ethical statement (Item 5). Endorsement of the ARRIVE guidelines has promoted the reporting rate of this item to a certain extent, but only to 7.74%. Nikki Osborne *et al.* conducted an ethical review of journals that had published original studies on animals, and the results indicated that a considerable number of journals have not made this a mandatory requirement<sup>[16]</sup>. A number of studies have shown<sup>[17]</sup> that at least 20

million animals are used in scientific experiments every year in China, of which approximately 25% suffer pain from the procedure, but approximately 10% are not administered painkillers. An analysis of the ethical status of experimental animals in China by Chen Jie *et al.* [18] demonstrated these serious problems, where animals are used as a tool to obtain experimental data without considering any suffering they may have to tolerate in the process of experimentation. **Highly distressed laboratory animals may lead to unreliable conclusions and/or unnecessary changes in scientific output, thereby affecting the reliability and repeatability of experiments, therefore every effort should be made to reduce unnecessary harm to them** [9]. Although all countries have successively introduced laws and policies on animal welfare, and have even established animal protection organizations to supervise the regulations [19,20], Olsson [21] and other researchers have also discussed how better to promote the issue. However, **efforts on animal welfare remain unsatisfactory**. Therefore, it is necessary to further regulate animal experimentation through legislation. More attention should be paid to animal ethics, **adhering to the "3Rs" principle, and respecting the value and rights of animals**.

☒ **Study design:** After 2010, although more studies used time-line diagrams or flow charts to illustrate the entire process of study design and conduct of the research (item 6d), the actual compliance rate was only 2.31%. A number of studies have shown that more than half of preclinical studies are unrepeatable [22], due to deficiencies in study design, incorrect statistical analysis and inadequate reporting [8, 23, 24]. Therefore, a clear and detailed flow chart can be effective in displaying the entire process of the experiment and improve the transparency of experimental implementation.

☒ **Experimental procedures:** Of the animal studies published in Chinese journals, only 6.20% and 11.81% of studies provided dates of experiments (item 7b) or experimental sites (item 7c). One study [25] demonstrated that it was not possible to scientifically evaluate the reliability of the results in 76 articles describing animal experimentation (with more than 500 citations) due to a lack of reporting of key methodological information including experimental process and procedures. Detailed reporting of **experimental processes and procedures** is a key measure to ensure replication of the results is possible and improve their utilization and conversion rate.

☒ **Housing and husbandry conditions:** Although research published after 2010 showed that the compliance rate of housing (item 9a) and husbandry conditions (item 9b) improved ( $P < 0.001$ ), actual compliance rates were only 29.46% and 28.35%, respectively. It is well known that the type of cage or housing, style of settlement, light/dark cycle, temperature, and water quality will impact experimental results. In addition, Hooijmans *et al.* [2, 26-28] pointed out in their research that there can be a four-fold difference in light intensity between cages at the top or bottom of a rack, and small differences such as these have been associated with animal reproduction and behavior.

☒ **Sample size:** Of 4342 animal studies published in Chinese journals, only one study reported the **algorithm** and formula for calculating sample size (item 10b), and only six studies indicated the number of independent replications of each experiment (item 10c). The National Institute of Neurological Disorders and Stroke (NINDS) reached a consensus in 2012 on how to improve reporting in animal

research reports in the process of submitting articles and using funding, in which they noted <sup>[29]</sup> “insufficient sample size may lead to false negative results, and miss some potentially important discoveries”. Therefore, it is necessary to report the number of animals used in each group and which statistical methods were used to determine the sample size.

☒ Allocation of animals to experimental groups: Although the rate of reporting of specific grouping methods for experimental animals published after 2010 (item 11a) was significantly higher than those published before 2010 ( $P < 0.001$ ), the actual coincidence rate was only 12.02%. A number of studies have shown <sup>[8]</sup> that randomization, allocation concealment and blinding are important methods to reduce the risk of bias in an intervention animal experiment.

## Results and discussion

In the ARRIVE Guidelines, the results and discussion sections include "baseline data, numbers analyzed, outcomes and estimation, adverse events, interpretation/scientific implications, generalizability/translation, and funding". The research in the present study showed that:

☒ Adverse events: The majority of animal experiments published in China (4278/4342, 98.53%) did not report details of important adverse events in experiments (item 17a). Researchers also need to pay attention to adverse events and analyze their nature, an important aspect for judging the pros and cons of an intervention. Therefore, accurate assessment and reporting of adverse events should not be neglected.

☒ Interpretation/scientific implications: Only 5.25% of the 4342 animal experiments published in Chinese journals reported limitations (item 18b) and only 0.35% described the significance of their research methods or findings in terms of the 3R principles (item 18c). The purpose of scientific design is to reduce any bias that may be experienced during experimentation. However, in terms of specific implementation, such as the animal model used, any potential source of bias in the experimental process, and factors affecting the accuracy of the study will reduce the scientific significance of the study <sup>[11]</sup>. Therefore, it is necessary for the author to objectively evaluate and explain the reasons in the discussion section of the article in order to ensure that the study remains scientifically valid while helping users understand the conclusions. In addition, the implementation of animal experiments should follow the 3Rs (replacement, refinement, and reduction of animals in research), the core of which is to protect, and use fewer, or zero, animals <sup>[1, 30]</sup>. Scientific experimental design can reduce the number of experimental animals <sup>[31, 32]</sup>. Experimental technology and optimized [research](#) procedures can reduce pain and anxiety in animals in experimental procedures <sup>[32]</sup>. [Flecknell retrospectively studied the use and analgesic effects of perioperative and postoperative anesthesia in animal experimentation, suggesting that appropriate anesthesia and analgesic programs should be adopted in future animal studies and that animal welfare should be sufficiently considered on the premise of meeting legal requirements](#) <sup>[33, 34]</sup>. Therefore, it is necessary for authors to interpret the scientific implications in the discussion section of the paper, which

can help readers fully evaluate the research information, promote the implementation and the 3Rs principle, thereby improving the quality of the animal experiments.

There are a number of limitations to this study: ☐ it was based only on the evaluation of animal experimentation published in Chinese journals. The results may not represent the quality of the research of Chinese researchers published in foreign peer-reviewed journals; ☐ only interventional animal experiments were included. The results do not represent the quality of reports of other types of animal experiments.

In summary, the reporting quality of animal experiments based on the ARRIVE guidelines in China is generally at a low to moderate level. In particular, insufficient reporting in methods, including an ethical statement, study design, experimental procedures, sample size, and allocation of animals to experimental groups provides evidence that researchers fail to fully understand the whole process of study design and implementation and, to a certain extent, hinder the transformation and utilization of research achievements. In addition, it should be pointed out that even though the [criterion](#) for achieving a "low risk" classification in our study was not particularly strict or rigorous, the results of reporting quality remain rather poor. Additional problems would be exposed if the study were conducted in compliance with strict [criteria](#). However, an RCT conducted by Hair *et al.* <sup>[35]</sup> indicated that low compliance during the implementation of the ARRIVE guidelines may be due to the fact that journals only require authors to submit lists when they contribute, rather than editors having to review them according to the lists, hindering any improvement in the quality of experimental animal study reporting. Furthermore, we should also point out a number of existing problems in the current ARRIVE guidelines. Therefore, ARRIVE 2019 <sup>[36]</sup> has been optimized for rigor and transparency in comparison with the 2010 version, being more convenient for journals, institutions or researchers to understand and use by listing animal care and management separately. Therefore, the ARRIVE guidelines should be popularized, and researchers encouraged to follow them in the future, in particular, the ARRIVE guidelines should be promoted in specialized journals. Additionally, we also suggest that in practical research, animal ethics and welfare issues should be truly embraced. Where improvements in the design, implementation, and reporting of animal experiments are introduced, improvements in quality will ultimately follow.

## Declarations

### Data Availability Statement

All relevant data are available either within the paper or the Supporting Information files.

### Competing interests

All authors declare that no competing interests exist.

### Funding Sources

The project was supported by the National Natural Science Foundation of China (project number: 81873184) and Basic Scientific Research Projects of Central Colleges and Universities of Lanzhou University (project number: lzujbky-2018-96).

## Author Contributions

B.Z., Y.B.J., J S.W.K., and B.M. were responsible for the conception and design of the study. B.Z. analyzed and interpreted the results in collaboration with Y.B.J., T.Z., Z.Z.S., WY.Z., KY.H., F.C., F.M., Q.Q.G., and L.Z., who were responsible for acquisition of the data. B.Z., Y.B.J., and B.M. wrote the first draft of the article. All authors critically revised the article for important intellectual content and approved the final version of the manuscript.

## Acknowledgments

We thank Professor Yuanyuan Zhang (Lanzhou University) for her contributions of text editing and article modification to this study.


## References

1. ZM He, RC Xing, XY Fang, LZ Wang, CL Shang. On Laboratory Animal Welfare, Animal Experiments and Alternative Methods of Animal Experiments. *Laboratory Animal Science and Management* 2005; 22 (1): 61-4.
2. Hooijmans CR, Rovers MM, De Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. *BMC Med Res Metholo* 2014; 14 (1): 1-9.
3. Sandercock P, Roberts I. Systematic reviews of animal experiments. *Lancet* 2002; 360 (9333):586.
4. Festing MF. The scope for improving the design of laboratory animal experiments. *Lab Anim* 1992; 26 (4): 256-68.
5. Festing MF, Nevalainen T. The Design and Statistical Analysis of Animal Experiments: Introduction to this Issue. *I lar Journal* 2014; 55 (3): 379-82.
6. Macleod MR, Ebrahim S, Roberts I. Surveying the literature from animal experiments: Systematic review and meta-analysis are important contributions. *BMJ* 2005; 331 (7508): 110.
7. Rómulo CE, Ricardo PM. OPL105. Systematic review and meta-analysis of the efficacy of tPA in experimental stroke. *J. Cereb Blood Flow Metab* 2005; 25 (6): 713-21.
8. Kilkeny C, Parsons N, Kadyszewski E, Festing MF, Cuthill IC, Fry D. Survey of the Quality of Experimental Design, Statistical Analysis and Reporting of Research Using Animals. *PLoS One* 2009; 4 (11): e7824.
9. Prescott, M.J. and K. Lidster, Improving quality of science through better animal welfare: the NC3Rs strategy. *Lab Animal*, 2017. 46(9).

10. Begg C, Cho M, Eastwood S, Horton R, Moher D, Olkin I et al. Improving the quality of reporting of randomized controlled trials. The CONSORT statements. *JAMA* 1996; 122 (8): 637-9.
11. Browne WJ, Emerson M, Altman DG. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. *PLoS Biol* 2010; 8(6): e000412.
12. Gulin JE, Rocco DM, Garcíabournissen F. Quality of Reporting and Adherence to ARRIVE Guidelines in Animal Studies for Chagas Disease Preclinical Drug Research: A Systematic Review. *ISO: PLoS Neglect Trop. Dis* 2015; 9(11): e0004194.
13. Schwarz F, Iglhaut G, Becker J. Quality assessment of reporting of animal studies on pathogenesis and treatment of peri-implant mucositis and peri-implantitis. A systematic review using the ARRIVE guidelines. *J. Clin Periodontol* 2012; 39(12): 63-72.
14. Sharmila Jalgaonkar, Tausif Mapara, Apoorv Verma, Mohsin Sayyed. Comparison of adherence to ARRIVE guidelines in animal research articles published in the years 2009 and 2016 in pharmacology journals: An observational study[J]. *Journal of Pharmacology and Pharmacotherapeutics*, 2019, 10(3).
15. YL Liu, XX Zhao, YF Mai, XX Li, J Wang, LL Chen, et al. Adherence to ARRIVE Guidelines in Chinese Journal Reports on Neoplasms in Animals. *PLoS One* 2016; 11(5): e0154657.
16. Osborne NJ, Payne D, Newman ML, Journal editorial policies, animal welfare, and the 3Rs. *Am J Bioeth* 2009; 9: 55–59
17. Yu J, Fan P, Chen L. Overview of the Development of Animal Welfare Ethics in Foreign Countries and Its Reference Significance [C]. *Science and Technology Exchange of Laboratory Animals in Central and South China*. 2009.
18. J Chen, T Yu, W Liu, WW Dong, QY Xian. Reflections on the Ethical Problems of Laboratory Animals in Scientific Research in China. *Agricultural Science and Technology Management* 2014; 33(6): 22-4.
19. Mohan, S. and R. Huneke, The Role of IACUCs in Responsible Animal Research. *Ilar Journal*, 2019. 60(1): p. 43-49
20. Weber, T., The Ethical Evaluation of Animal Experiments Deserves More Than Empty Phrases. *Altex-Alternatives To Animal Experimentation*, 2018. 35(4): p. 518-519.
21. Olsson, I.A.S., S.P. da Silva, D. Townend, et al., Protecting Animals and Enabling Research in the European Union: An Overview of Development and Implementation of Directive 2010/63/EU. *Ilar Journal*, 2016. 57(3): p. 347-357.
22. Freedman LP, Cockburn IM, Simcoe TS. The Economics of Reproducibility in Preclinical Research. *PLoS. Biol* 2015; 13(6): e1002165.
23. Begley CG, Ellis LM. Drug development: Raise standards for preclinical cancer research. *Nature* 2012; 483(7391): 531-3.

24. Begley CG, Ioannidis JP. Reproducibility in Science: Improving the Standard for Basic and Preclinical Research. *Circ Res* 2015; 116(1):116-26.
25. Hackam D G, Redelmeier D A. Translation of research evidence from animals to humans. *JAMA* 2006; 296(14):1731-2.
26. Johnston NA, Nevalainen T. Impact of biotic and abiotic environment on animal experiments. In *Handbook of Laboratory Animal Science (Book 1)*. 3rd edition. Edited by Hau JS. Raton B. Florida: CRC Press, 2010: 343-69.
27. Donnelly H, Saibaba P. Light intensity and the oestrous cycle in albino and normally pigmented mice. *Lab. Anim* 1993; 27(4): 385-90.
28. Vanderschuren LJMJ, Niesink RJ, Spruijt BM, Van Ree JM. Influence of environmental factors on social play behavior of juvenile rats. *Physiol Behav* 1995; 58(1): 119-23.
29. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW *et al*. A call for transparent reporting to optimize the predictive value of preclinical research. *Nature* 2012; 490(7419): 187-91.
30. DY Ye, J Sun, RF Li, RL Zuo, YQ Li. Research Progress on the Implementation of Laboratory Animal Welfare. *Laboratory Animal and Comparative Medicine* 2017; 37(2): 166-70.
31. Johnson PD, Besselsen DG. Practical aspects of experimental design in animal research. *Ilar Journal* 2002; 43(4): 202-6.
32. Shaw R, Festing M F, Peers I, Furlong L. Use of factorial designs to optimize animal experiments and reduce animal use. *Ilar Journal* 2002; 43(4):223-32.
33. Kathrin, H. and F. Paul, Retrospective review of anesthetic and analgesic regimens used in animal research proposals. *ALTEX*, 2019. 36(1).
34. Bertrand, H.G.M.J., C. Sandersen and P.A. Flecknell, Reported analgesic and anaesthetic administration to non-human primates undergoing experimental surgical procedure: 2010-2015. *Journal of Medical Primatology*, 2018. 47(4).
35. Hair K, Macleod MR, Sena ES; IICARus Collaboration. A randomised controlled trial of an Intervention to Improve Compliance with the ARRIVE guidelines (IICARus). *Res Integr Peer Rev*. 2019;4:12.
36. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2019: Updated guidelines for reporting animal research. Submitted to *Plos Biology*. 2019.

## Figures



**Figure 1 Flowchat for selecting process and results**

\*Retrieved databases and selected studies as follows: CNKI (n=1 213), Wanfang (n=5 500), VIP (n=1 702), CBM (n=13 298).

## Figure 1

Flow chart for the selection process and results \*Retrieved databases and selected studies as follows: CNKI (n=1 213), WanFang (n=5 500), VIP (n=1 702), CBM (n=13 298)




Figure2: The species of laboratory animals and interventions of animal test reports in Chinese journals

Figure 2

Laboratory animal species and interventions of animal test reports published in Chinese journals.

Figure 3 Assessment of reporting quality of inclusive studies




Figure 3

Reporting quality of inclusive studies

## Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [S1File.docx](#)
- [PRISMA2009checklist.doc](#)